Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

• Published in: Journal of translational medicine Vol. 19; no. 1; pp. 1 - 415
• Main Authors: Meng, Jinyu, Peng, Jin, Feng, Jie, Maurer, Jochen, Li, Xiao, Li, Yan, Yao, Shu, Chu, Ran, Pan, Xiyu, Li, Junting, Zhang, Ting, Liu, Lu, Zhang, Qing, Yuan, Zeng, Bu, Hualei, Song, Kun, Kong, Beihua
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 07.10.2021; BioMed Central; BMC
• Subjects: Antibodies; Antigens; Antitumor agents; Apoptosis; Cancer therapies; CD8 antigen; Cell activation; Cell culture; cGAS/STING pathway; Chemotherapy; CXCL10 protein; Cytokines; Cytotoxicity; Development and progression; Drug therapy; Enzyme-linked immunosorbent assay; Enzymes; FDA approval; Flow cytometry; Health aspects; Immune checkpoint; Immune response; Immunohistochemistry; Immunotherapy; Lymphocytes; Lymphocytes T; Metastases; Niraparib; Ovarian cancer; PARP inhibitors; PD-L1; PD-L1 protein; Physiological aspects; Poly(ADP-ribose) polymerase; Poly(ADP-ribose) Polymerase 1; Proteins; Ribose; Tumors; Western blotting; China; Canada; United States > US

Abstract Background Immune checkpoint blockades (ICBs) therapy showed limited efficacy in ovarian cancer management. Increasing evidence indicated that conventional and targeted therapies could affect tumor-associated immune responses and increase the effectiveness of immunotherapy. However, the eff...